Hassan, Mary Joy B.
HRN: 03-45-10 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/30/2023
CO-AMOXICLAV 625MG (TAB)
01/30/2023
02/06/2023
PO
625mg
Q8hrs
Fx Femur Left
Waiting Final Action
Indication: Empiric Type of Infection: Bone & Joint Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes